Category: Lawley Announcement

Categories: Lawley Announcement, hypoactive sexual desire dysfunction HSDD, low libido in women, testosterone for women, testosterone, menopause, early menopause

Reasons for PBAC denial of women’s testosterone therapy released: “inequitable” and “scientifically flawed”

Posted: March 26, 2026

MEDIA RELEASE – Embargo 12.00 am, 27 March 2026 Reasons for PBAC denial of women’s testosterone therapy released: “inequitable” and “scientifically flawed” Last Friday,… Continue Reading →

Categories: testosterone for women, Lawley Announcement, hypoactive sexual desire dysfunction HSDD, low libido in women, testosterone, menopause, hysterectomy, hormone research, early menopause

AUSTRALIAN MINNOW, LAWLEY PHARMACEUTICALS, TAKES PBAC TO FEDERAL COURT

Posted: February 10, 2026

MEDIA RELEASE – Wed 11 February 2026 AUSTRALIAN MINNOW, LAWLEY PHARMACEUTICALS, TAKES PBAC TO FEDERAL COURT A small Perth-based pharmaceutical company is stepping up… Continue Reading →

Categories: menopause, testosterone for women, Medical Professional News, hypoactive sexual desire dysfunction HSDD, Lawley Announcement

PBAC says NO!

Posted: December 19, 2025

The outcome of the November 2025 meeting of the Pharmaceuticals Benefits Advisory Committee (PBAC) has determined that AndroFeme® 1 testosterone cream for the treatment… Continue Reading →

Categories: early menopause, menopause, testosterone, testosterone for women, hypoactive sexual desire dysfunction HSDD, Lawley Announcement

MHRA approves testosterone cream for UK postmenopausal women

Posted: August 12, 2025

MHRA approves testosterone cream for UK postmenopausal women 12 August 2025 Perth, Australia and Guildford, England: Lawley Pharmaceuticals and its commercial… Continue Reading →

Categories: Lawley Announcement

Testosterone cream for postmenopausal women with HSDD submitted for UK licensing.

Posted: April 11, 2023

Perth, Australia and Guildford, England: Lawley Pharmaceuticals and its commercial partner in the UK, Andro Pharmaceuticals Ltd, are pleased to announce that a Marketing… Continue Reading →

Categories: Lawley Announcement

Wishing you a Wonderful Christmas and Happy New Year

Posted: December 13, 2022

To our valued and loyal Customers, As Christmas is rapidly approaching, we would like to take this opportunity to thank you for being a… Continue Reading →

Categories: early menopause, menopause, hypoactive sexual desire dysfunction HSDD, Lawley Announcement

Australasian Menopause Society Congress: 9-11 September

Posted: August 11, 2022

AMS Congress 2022 Visit us in Cairns!!! The AMS is pleased to announce the 25th Annual Australasian Menopause Society Congress will be held at… Continue Reading →

Categories: hormone research, menopause, Medical Professional News, Lawley Announcement

Monash University: Bone Density Study

Posted: April 28, 2022

A study to prevent bone loss and restore sexual function in women with primary ovarian insufficiency Melbourne and Perth As many as 4 in… Continue Reading →

Categories: hormone research, menopause, Lawley Announcement

Monash University: Bone Density Study

Posted: April 28, 2022

A study to prevent bone loss and restore sexual function in women with primary ovarian insufficiency Melbourne and Perth As many as 4 in… Continue Reading →

Categories: testosterone for women, Lawley Announcement, hypoactive sexual desire dysfunction HSDD, low libido in women

AndroFeme 1 included on ARTG for hypoactive sexual desire dysfunction in postmenopausal women

Posted: February 17, 2021

Lawley Pharmaceuticals’ female-specific hormone cream, AndroFeme® 1, has been registered on the Australian Register of Therapeutic Goods (ARTG) for the treatment of postmenopausal women… Continue Reading →

1 2 Next Page »